Cohort Primary Hyperparathyroidism
Launched by NANTES UNIVERSITY HOSPITAL · Jul 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Cohort Primary Hyperparathyroidism trial is studying the effects of a surgery called parathyroidectomy on patients diagnosed with primary hyperparathyroidism. This condition occurs when one or more of the parathyroid glands (small glands in the neck) produce too much parathyroid hormone, which can lead to health issues like heart problems, kidney issues, and weakened bones. The trial aims to find out if having this surgery can improve these health outcomes and enhance the quality of life for patients.
To participate, adults over 18 years old who have been diagnosed with primary hyperparathyroidism are eligible. However, those who are pregnant, breastfeeding, under legal guardianship, or have other specific medical conditions are not included. Participants will undergo medical evaluations when they join the study and at various points over the next five years to monitor their health and collect samples for research. This study is currently recruiting participants at Nantes University Hospital, and it is an opportunity for patients to contribute to important research that could benefit others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Age \> 18
- Exclusion Criteria:
- • Age \< 18
- • Pregnancy / lactation
- • Adults underguardianship
- • Secondary/tertiary hyperparathyroidism
- • Multiple endocrine neoplasia
About Nantes University Hospital
Nantes University Hospital, a leading academic medical institution in France, is dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific exploration with patient care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, Nantes University Hospital aims to contribute to the development of effective therapies and interventions that enhance patient outcomes and overall public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nantes, Loire Atlantique, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials